All In Biotech

Drug Trial Radar · NCT00947960

Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease

A Treatment Trial of Triheptanoin in Patients With Adult Polyglucosan Body Disease - A Randomized Controlled Study

Last checked: Nov 20, 2026Latest source record: Mar 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

23

Actual

Start

Jun 2009

Primary completion

Jul 2015

Study completion Jul 2015

Sponsor

Lead sponsor
Baylor Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ultragenyx Pharmaceutical Inc
First posted
Jul 28, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine if triheptanoin is an effective treatment for the symptoms of Adult Polyglucosan Body Disease.

Conditions

  • Adult Polyglucosan Body Disease
  • Glycogen Brancher Enzyme Deficiency
  • Glycogen Storage Disease Type IV

Interventions

  • TriheptanoinDrug

    1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.

  • Vegetable OilOther

    1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 g triheptanoin (drug)/kilogram body weight for 6 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Distance traveled in six minute walk testTime frame: every three months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Genetics, Groupe Hospitalier Pitié-Salpêtrière

    Paris, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.